文献速递消化、代谢与肾脏急症

急诊科肌注酮咯酸治疗急性肌肉骨骼疼痛:两种剂量比较

Comparing two doses of intramuscular ketorolac for treatment of acute musculoskeletal pain in a military emergency department.
PubMed 文献 · Am J Emerg Med · 2021-07-31
一句话结论在急诊成人急性肌肉骨骼疼痛中,肌注酮咯酸15 mg在60分钟疼痛改善上非劣于60 mg,且轻微不良反应更少。

主要终点为基线至60分钟疼痛VAS评分变化的组间均值差,结果为0.2 mm(95%CI -8.5-8.7;30分钟VAS变化均值差为-1.7 mm(95%CI -8.5-5.1;

要点

  • 急诊成人急性肌肉骨骼疼痛,肌注酮咯酸15 mg与60 mg在60分钟VAS疼痛改善的均值差为0.2 mm(95%CI -8.5-8.7),小于非劣效界值13 mm。
  • 30分钟VAS疼痛改善的组间均值差为-1.7 mm(95%CI -8.5-5.1),同样小于13 mm非劣效界值。
  • 两组均未报告严重不良反应。
  • 研究结论建议考虑停止以60 mg肌注酮咯酸替代更低剂量用于急诊急性肌肉骨骼疼痛的做法。

适用人群与场景

  • 急诊科就诊、主诉为急性肌肉骨骼疼痛的成人患者。

诊断标准与关键阈值

  • 非劣效界值预设为VAS评分组间均值差13 mm。

处置流程与药物剂量

  • 第一步:对急诊成人急性肌肉骨骼疼痛患者,可考虑肌注酮咯酸15 mg作为60 mg的替代剂量(原文结论支持15 mg非劣于60 mg)。
  • 给药途径为肌内注射,原文未提及频次或疗程。

红旗征与不能漏的情况

  • 原文未提及需要立即处理或不能漏诊的红旗征。

研究设计与关键结果

  • 人群:急诊就诊的急性肌肉骨骼疼痛成人。
  • 干预与对照:肌注酮咯酸15 mg vs 60 mg。

证据类型、等级与局限

  • 证据类型:单盲随机对照非劣效性试验。

对床旁实践的改变

  • 对于急诊成人急性肌肉骨骼疼痛,可考虑将肌注酮咯酸剂量从60 mg降至15 mg,因15 mg在60分钟和30分钟疼痛改善上均非劣于60 mg,且轻微不良反应更少。
  • 适用人群为急诊就诊的急性肌肉骨骼疼痛成人;原文未提及排除人群,不适用人群原文未提及。
  • 常见陷阱:原文未提及。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

STUDY OBJECTIVE: The goal of the study was to assess a low-dose versus a high-dose of intramuscular (IM) ketorolac for non-inferiority in adults with acute MSK pain in an emergency department (ED).

METHODS: This was a single-blinded, randomized controlled, non-inferiority trial of adults presenting to an ED with a chief complaint of acute MSK pain. Patients were randomized to either a 15 mg or a 60 mg IM ketorolac dose. The primary outcome was the mean difference of change in pain from baseline to 60-min between the two groups as reported on a 100-mm (mm) visual analog scale (VAS). Secondary outcomes included the mean difference of change in VAS scores at 30-min and the incidence of reported adverse effects associated with the administration of ketorolac.

RESULTS: One hundred ten patients were randomized with 55 in each group. The mean difference in pain between groups at 60-min (0.2 mm [95% CI -8.5-8.7]; p = .98) and 30 min (-1.7 mm [95% CI -8.5-5.1; p = .63) was less than the predetermined non-inferiority margin of 13 mm. There were no major adverse effects reported. Minor adverse effects were more frequent in the 60 mg group (n = 9; 16.4% vs. n = 1; 1.8%; p = .016) with burning at the injection site being the most commonly reported.

CONCLUSIONS: A 15 mg dose of IM ketorolac was found to be non-inferior to a 60 mg dose for acute MSK pain in adults presenting to the ED. Discontinuing the practice of ordering 60 mg doses of IM ketorolac in place of a lower dose for acute MSK pain should be considered.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Turner NJ, Long DA, Bongiorno JR, et al. Comparing two doses of intramuscular ketorolac for treatment of acute musculoskeletal pain in a military emergency department. Am J Emerg Med. 2021. PMID: 34365063. doi:10.1016/j.ajem.2021.07.054

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。